Kazakhstan may become the largest pharmaceutical hub
in Central Asia. Agreements on localization of production in the country have
been signed with three foreign pharmaceutical giants: Pfizer, Roche, and
AstraZeneca. Notably, AstraZeneca is ready to manufacture four innovative drugs
in the country. The first batch of one of these medicines, aimed at treating
kidney disease, heart failure, and type 2 diabetes, is expected to enter the
market in 2025. The production of the remaining three drugs for cancer therapy
is also planned for the near future. Overall, the company plans to invest
around seven billion euros, with funds also being directed to the scientific practice
of Kazakh specialists.
«We have already
launched one real-world clinical practice study, it has been registered, and
Kazakh doctors have been selected to participate in this international study.
Additionally, we are currently registering the country's first phase III
clinical trial involving Kazakh patients. This is very important since it brings
the country into the international arena in terms of drug efficacy before and
after registration,» said Maria Shipuleva, Director of the Astrazeneca Kazakhstan.
«We have already
set a goal to achieve 50 percent domestic production by 2029. If companies
enter Kazakhstan to open their production facilities, they should first
consider reducing production costs. This is a requirement we impose on all
investors entering the market. All the companies entering now are not only
focused on localization, but they also come with training seminars, workshops,
bringing in experts and doctors from abroad for training,» noted Dinara Issabekova, Project
Manager at the Kazakh Invest.
Web-editor: Әсел Бақытқызы
Related Articles
